Coherus Oncology (NASDAQ:CHRS – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday, Wall Street Zen reports.
Several other research analysts also recently commented on the stock. Weiss Ratings downgraded shares of Coherus Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 10th. HC Wainwright started coverage on Coherus Oncology in a report on Thursday, October 29th. They set a “buy” rating for the company. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.00.
View Our Latest Stock Analysis on CHRS
Coherus Oncology Stock Performance
Coherus Oncology (NASDAQ:CHRS – Get Free Report) last posted its earnings results on Monday, November 9th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The company had revenue of $14.27 million for the quarter, compared to the consensus estimate of $15.90 million. Coherus Oncology had a negative net margin of 253.43% and a negative return on equity of 274.46%. Analysts forecast that Coherus Oncology will post -0.86 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Coherus Oncology during the 2nd quarter worth $16,805,000. GSA Capital Partners LLP purchased a new stake in shares of Coherus Oncology in the 2nd quarter valued at about $531,000. Cetera Investment Advisers acquired a new position in shares of Coherus Oncology in the first quarter valued at approximately $54,000. Jefferies Financial Group Inc. acquired a new position in shares of Coherus Oncology during the second quarter worth about $353,000. Finally, Empowered Funds LLC acquired a new position in shares of Coherus Oncology during the 3rd quarter worth $212,000. 72.82% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Coherus Oncology
These are some of the CHRS headlines that stood out recently:
- Negative Sentiment: HC Wainwright trimmed estimates for FY2026–FY2029, including FY2026 EPS from ($0.84) to ($0.89), FY2027 from ($0.63) to ($0.68), FY2028 from ($0.48) to ($0.54), and FY2029 from ($0.19) to ($0.26). It also lowered estimates for Q4 2026 and each quarter of 2027. These revisions point to greater expected losses in the near term and beyond. MarketBeat coverage
- Neutral Sentiment: Despite lowering its forecasts, HC Wainwright kept its Buy rating on CHRS. MarketBeat coverage
Coherus Oncology Company Profile
Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer. The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology.
Further Reading
- Five stocks we like better than Coherus Oncology
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
